Despite the contribution of EGFR-mediated EMT to therapy resistance, a recent Cochrane meta-analysis demonstrated little or no survival benefit from anti-EGFR treatment in ovarian cancer patients [110]. This evidence concerns the gene EGFR and ovarian cancer.